论文部分内容阅读
糖尿病是一种以高血糖为特征的代谢性疾病,目前常用的口服降糖药均需要每天服药,给患者带来不便。奥格列汀是一个小分子二肽基肽酶-4(DPP-4)抑制剂,由默克公司研发,主要用于二型糖尿病的治疗,且只需1周服用1次即可,从而提高了患者的顺应性和坚持性,最终提高了治疗效果。介绍了奥格列汀的合成方法、药理学、药物代谢动力学、临床研究等信息,为更好地应用临床与研发类似新药提供依据。
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia. Currently, oral hypoglycemic agents commonly used in hospitals need daily medication and inconvenience to patients. Olinotropin, a small molecule dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck, is mainly used for the treatment of type 2 diabetes mellitus and takes only once a week Improve patient compliance and persistence, and ultimately improve the treatment effect. Introduced the synthesis of otogliptin, pharmacology, pharmacokinetics, clinical research and other information, to provide a basis for the better application of clinical and research and development of similar new drugs.